CRP and metabolic dysfunction-associated steatotic liver disease: Incidence of C-reactive protein (CRP) >5 mg/L, of metabolic (dysfunction)-associated fatty liver disease (MAFLD; previously called nonalcoholic fatty liver disease) (31, 32), and of arterial hypertension showed a significant progressive increase from NFG to IFG and to DM.